Krystal Biotech (KRYS) to Release Earnings on Monday

Krystal Biotech (NASDAQ:KRYS) is anticipated to post its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect Krystal Biotech to post earnings of $1.04 per share and revenue of $93.7230 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Monday, November 3, 2025 at 8:30 AM ET.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The firm had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. On average, analysts expect Krystal Biotech to post $6 EPS for the current fiscal year and $10 EPS for the next fiscal year.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $186.13 on Monday. The firm has a fifty day moving average of $164.99 and a 200-day moving average of $151.96. The stock has a market cap of $5.39 billion, a price-to-earnings ratio of 37.83 and a beta of 0.64. Krystal Biotech has a 52-week low of $122.80 and a 52-week high of $207.84.

Hedge Funds Weigh In On Krystal Biotech

A number of institutional investors and hedge funds have recently bought and sold shares of KRYS. Osaic Holdings Inc. grew its holdings in shares of Krystal Biotech by 41.4% during the second quarter. Osaic Holdings Inc. now owns 393 shares of the company’s stock worth $54,000 after purchasing an additional 115 shares during the last quarter. Empowered Funds LLC acquired a new position in Krystal Biotech during the 1st quarter worth about $218,000. Royal Bank of Canada grew its holdings in Krystal Biotech by 145.2% during the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after acquiring an additional 964 shares during the last quarter. EP Wealth Advisors LLC grew its holdings in Krystal Biotech by 4.0% during the 2nd quarter. EP Wealth Advisors LLC now owns 2,726 shares of the company’s stock worth $375,000 after acquiring an additional 105 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Krystal Biotech by 310.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,998 shares of the company’s stock valued at $412,000 after acquiring an additional 2,268 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on KRYS shares. Bank of America increased their price target on shares of Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Guggenheim set a $224.00 price objective on Krystal Biotech and gave the company a “buy” rating in a research note on Friday, October 17th. Chardan Capital cut their target price on Krystal Biotech from $219.00 to $216.00 and set a “buy” rating for the company in a research report on Friday, August 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $240.00 price target on shares of Krystal Biotech in a research note on Monday, September 15th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Krystal Biotech in a research note on Saturday. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $223.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).